GlassScriptPhysician profile
Manmeet Sandhu
NPI 1639355910
$3,428.59
in general payments reported to CMS, 2019-2025
29 companies · $640 in 2025
The $640 reported for 2025 was more than what 85% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $348 · 2020: $44.29 · 2021: $573 · 2022: $910 · 2023: $451 · 2024: $463 · 2025: $640.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,517 · Travel and Lodging: $37.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,516.82 |
| Travel and Lodging | $37.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aspira Women'S Health INC | $962.05 | 2020-2024 | Ova1 |
| Intuitive Surgical, INC. | $427.68 | 2025 | |
| Abbvie INC. | $356.49 | 2019-2022 | |
| Hologic Sales and Service, LLC | $292.71 | 2019-2025 | Aptima, Acessa Provu System, Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Organon LLC | $210.82 | 2021-2025 | Nexplanon |
| Biogen, INC. | $173.18 | 2024-2025 | Zurzuvae |
| Exeltis, USA INC. | $161.29 | 2021-2025 | Slynd |
| Allergan, INC. | $136.04 | 2019 | |
| Pfizer INC. | $126.86 | 2019-2023 | |
| Mayne Pharma Commercial LLC | $72.52 | 2023 | |
| Pacira Pharmaceuticals Incorporated | $64.67 | 2022 | |
| Merck Sharp & Dohme LLC | $55.32 | 2019-2023 | Gardasil 9 |
| Daiichi Sankyo INC. | $51.25 | 2019-2021 | |
| Coopersurgical, INC. | $44.23 | 2021-2025 | Endosee |
| Myovant Sciences INC. | $35.20 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $33.70 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $28.59 | 2024-2025 | Myfembree |
| Innovation Technologies INC | $24.11 | 2025 | Irrisept |
| Agile Therapeutics, INC. | $23.59 | 2022 | |
| Duchesnay USA Incorporated | $18.40 | 2019 | |
| Aspen Surgical Products, INC. | $17.00 | 2023 | |
| Shield Therapeutics INC | $16.12 | 2022 | |
| Smith+Nephew, INC. | $15.66 | 2022 | |
| Meditrina | $14.65 | 2023 | |
| Amag Pharmaceuticals, INC. | $14.06 | 2019 | |
| Therapeuticsmd, INC. | $13.73 | 2021 | |
| Evofem Biosciences, INC. | $13.49 | 2021 | |
| Astellas Pharma US INC | $13.15 | 2023 | Veozah |
| Amgen INC. | $12.03 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manmeet Sandhu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.